Role of new noninvasive methods in guiding the diagnosis and treatment of autoimmune hepatitis

Huaie LIU; Jiandan QIAN; Chi ZHANG; Yiqi LIU; Zhi LI; Hong ZHAO; Guiqiang WANG

doi:10.3969/j.issn.1001-5256.2022.04.034

Volume 38 Issue 4

Apr. 2022

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2022 > 38(4): 908-912

PDF( 1911 KB)

Role of new noninvasive methods in guiding the diagnosis and treatment of autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2022.04.034

Huaie LIU^{1, 2},
Jiandan QIAN¹,
Chi ZHANG¹,
Yiqi LIU¹,
Zhi LI¹,
Hong ZHAO^{1
,
,
,},
Guiqiang WANG^{1, 3
,
,
,}

1.
Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China
2.
Department of Infectious Diseases, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, China
3.
Department of Infectious Diseases, Peking University International Hospital, Beijing 100034, China

Research funding:

Yunnan Province High-level Health Talent Project (H-2017071);

Yunnan Provincial Department of Education Research Fund (2021J0239)

More Information

Corresponding author: ZHAO Hong, zhaohong_pufh@btmu.edu.cn(ORCID: 0000-0002-8069-9901); WANG Guiqiang, john131212@sina.com(ORCID: 0000-0002-0317-7536)
Received Date: 2021-07-29
Published Date: 2022-04-20

Abstract

Abstract

Autoimmune hepatitis (AIH) is an inflammatory disease of the liver mediated by autoimmune response, and in the diagnosis and treatment of AIH, it is of great importance to accurately assess the progression of liver inflammation, screen out the patients requiring corticosteroid therapy, and evaluate the therapeutic outcome. This article introduces a variety of new noninvasive techniques which have been discovered by clinical and experimental studies in recent years and have the potential to evaluate the progression of AIH, as well as the advantages and disadvantages of each technique. It is concluded that the new noninvasive techniques have more advantages in guiding the corticosteroid therapy for AIH, but further clinical studies are still needed for verification.
- Hepatitis, Autoimmune,
- Diagnosis,
- Therapeutics

FullText(HTML)

References(40)

References

[1]	GRØNBÆK L, VILSTRUP H, JEPSEN P. Autoimmune hepatitis in Denmark: Incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study[J]. J Hepatol, 2014, 60(3): 612-617. DOI: 10.1016/j.jhep.2013.10.020.
[2]	BISCHOFF S, YESMEMBETOV K, ANTONI C, et al. Autoimmune Hepatitis: A review of established and evolving treatments[J]. J Gastrointestin Liver Dis, 2020, 29(3): 429-443. DOI: 10.15403/jgld-2667.
[3]	European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Autoimmune hepatitis[J]. J Hepatol, 2015, 63(4): 971-1004. DOI: 10.1016/j.jhep.2015.06.030.
[4]	MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
[5]	WANG G, TANAKA A, ZHAO H, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidance: The diagnosis and management of patients with autoimmune hepatitis[J]. Hepatol Int, 2021, 15(2): 223-257. DOI: 10.1007/s12072-021-10170-1.
[6]	YEOMAN AD, WESTBROOK RH, ZEN Y, et al. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis[J]. Hepatology, 2011, 53(3): 926-934. DOI: 10.1002/hep.24141.
[7]	van GERVEN NM, VERWER BJ, WITTE BI, et al. Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission[J]. J Hepatol, 2013, 58(1): 141-147. DOI: 10.1016/j.jhep.2012.09.009.
[8]	DIESTELHORST J, JUNGE N, JONIGK D, et al. Baseline IL-2 and the AIH score can predict the response to standard therapy in paediatric autoimmune hepatitis[J]. Sci Rep, 2018, 8(1): 419. DOI: 10.1038/s41598-017-18818-5.
[9]	ROUAS R, FAYYAD-KAZAN H, EL ZEIN N, et al. Human natural Treg microRNA signature: Role of microRNA-31 and microRNA-21 in FOXP3 expression[J]. Eur J Immunol, 2009, 39(6): 1608-1618. DOI: 10.1002/eji.200838509.
[10]	LIU Y, CHEN H, HAO J, et al. Characterization and functional prediction of the microRNAs differentially expressed in a mouse model of concanavalin A-induced autoimmune hepatitis[J]. Int J Med Sci, 2020, 17(15): 2312-2327. DOI: 10.7150/ijms.47766.
[11]	TU H, CHEN D, CAI C, et al. MicroRNA-143-3p attenuated development of hepatic fibrosis in autoimmune hepatitis through regulation of TAK1 phosphorylation[J]. J Cell Mol Med, 2020, 24(2): 1256-1267. DOI: 10.1111/jcmm.14750.
[12]	MIGITA K, KOMORI A, KOZURU H, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis[J]. PLoS One, 2015, 10(11): e0136908. DOI: 10.1371/journal.pone.0136908.
[13]	CZAJA AJ. Emerging therapeutic biomarkers of autoimmune hepatitis and their impact on current and future management[J]. Expert Rev Gastroenterol Hepatol, 2018, 12(6): 547-564. DOI: 10.1080/17474124.2018.1453356.
[14]	KUNO A, IKEHARA Y, TANAKA Y, et al. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis[J]. Sci Rep, 2013, 3: 1065. DOI: 10.1038/srep01065.
[15]	URA K, FURUSYO N, OGAWA E, et al. Serum WFA(+) -M2BP is a non-invasive liver fibrosis marker that can predict the efficacy of direct-acting anti-viral-based triple therapy for chronic hepatitis C[J]. Aliment Pharmacol Ther, 2016, 43(1): 114-124. DOI: 10.1111/apt.13431.
[16]	UMEMURA T, JOSHITA S, SEKIGUCHI T, et al. Serum wisteria floribunda agglutinin-positive mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis[J]. Am J Gastroenterol, 2015, 110(6): 857-864. DOI: 10.1038/ajg.2015.118.
[17]	NISHIKAWA H, ENOMOTO H, IWATA Y, et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis[J]. Hepatol Res, 2016, 46(7): 613-621. DOI: 10.1111/hepr.12596.
[18]	BONGARZONE S, SAVICKAS V, LUZI F, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A medicinal chemistry perspective[J]. J Med Chem, 2017, 60(17): 7213-7232. DOI: 10.1021/acs.jmedchem.7b00058.
[19]	HUDSON BI, LIPPMAN ME. Targeting RAGE signaling in inflammatory disease[J]. Annu Rev Med, 2018, 69: 349-364. DOI: 10.1146/annurev-med-041316-085215.
[20]	WU R, LIU Y, YAN R, et al. Assessment of EN-RAGE, sRAGE and EN-RAGE/sRAGE as potential biomarkers in patients with autoimmune hepatitis[J]. J Transl Med, 2020, 18(1): 384. DOI: 10.1186/s12967-020-02556-w.
[21]	CHEN YY, JEFFERY HC, HUNTER S, et al. Human intrahepatic regulatory T cells are functional, require IL-2 from effector cells for survival, and are susceptible to Fas ligand-mediated apoptosis[J]. Hepatology, 2016, 64(1): 138-150. DOI: 10.1002/hep.28517.
[22]	HUANG H, DENG Z. Adoptive transfer of regulatory T cells stimulated by Allogeneic Hepatic Stellate Cells mitigates liver injury in mice with concanavalin A-induced autoimmune hepatitis[J]. Biochem Biophys Res Commun, 2019, 512(1): 14-21. DOI: 10.1016/j.bbrc.2019.02.147.
[23]	MATAKI N, KIKUCHI K, KAWAI T, et al. Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases[J]. Am J Gastroenterol, 2007, 102(2): 302-312. DOI: 10.1111/j.1572-0241.2006.00948.x.
[24]	XIONG KG, KE KY, CHEN LF, et al. The relationship between programmed death 1 and inflammatory response in autoimmune hepatitis[J]. Chin J Hepatol, 2017, 25(4): 263-267. DOI: 10.3760/cma.j.issn.1007-3418.2017.04.006. 熊克宫, 柯坤宇, 陈丽芳, 等. 自身免疫性肝炎患者肝内程序性死亡受体1高表达与肝脏炎症活动相关[J]. 中华肝脏病杂志, 2017, 25(4): 263-267. DOI: 10.3760/cma.j.issn.1007-3418.2017.04.006.
[25]	AGINA HA, EHSAN NA, ABD-ELAZIZ TA, et al. Hepatic expression of programmed death-1 (PD-1) and its ligand, PD-L1, in children with autoimmune hepatitis: Relation to treatment response[J]. Clin Exp Hepatol, 2019, 5(3): 256-264. DOI: 10.5114/ceh.2019.87642.
[26]	AARSLEV K, DIGE A, GREISEN SR, et al. Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis[J]. Scand J Gastroenterol, 2017, 52(1): 93-99. DOI: 10.1080/00365521.2016.1233576.
[27]	MATSUMOTO K, MIYAKE Y, MATSUSHITA H, et al. Anti-programmed cell death-1 antibody as a new serological marker for type 1 autoimmune hepatitis[J]. J Gastroenterol Hepatol, 2014, 29(1): 110-115. DOI: 10.1111/jgh.12340.
[28]	BREWER S, NAIR-GILL E, WEI B, et al. Epithelial uptake of[18F]1-(2'-deoxy-2'-arabinofuranosyl) cytosine indicates intestinal inflammation in mice[J]. Gastroenterology, 2010, 138(4): 1266-1275. DOI: 10.1053/j.gastro.2010.01.003.
[29]	SALAS JR, CHEN BY, WONG A, et al. (18)F-FAC PET selectively images liver-infiltrating CD4 and CD8 T Cells in a mouse model of autoimmune hepatitis[J]. J Nucl Med, 2018, 59(10): 1616-1623. DOI: 10.2967/jnumed.118.210328.
[30]	European Association for Study of Liver; Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis[J]. J Hepatol, 2015, 63(1): 237-264. DOI: 10.1016/j.jhep.2015.04.006.
[31]	YANG Q, LIU HE, YOU J, et al. Noninvasive diagnotisc models for chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2021, 37(10): 113-117. DOI: 10.3969/j.issn.1001-5256.2021.10. 杨琴, 刘怀鄂, 游晶, 等. 慢性乙型肝炎肝纤维化的无创诊断模型[J]. 临床肝胆病杂志, 2021, 37(10): 113-117. DOI: 10.3969/j.issn.1001-5256.2021.10.
[32]	MAHMUD N, DOSHI SD, FORDE KA, et al. Transient elastography reliably estimates liver fibrosis in autoimmune hepatitis[J]. Clin Exp Hepatol, 2019, 5(3): 244-249. DOI: 10.5114/ceh.2019.87639.
[33]	WU S, YANG Z, ZHOU J, et al. Systematic review: Diagnostic accuracy of non-invasive tests for staging liver fibrosis in autoimmune hepatitis[J]. Hepatol Int, 2019, 13(1): 91-101. DOI: 10.1007/s12072-018-9907-5.
[34]	GUO L, ZHENG L, HU L, et al. Transient elastography (FibroScan) performs better than non-invasive markers in assessing liver fibrosis and cirrhosis in autoimmune hepatitis patients[J]. Med Sci Monit, 2017, 23: 5106-5112. DOI: 10.12659/msm.907300.
[35]	HARTL J, EHLKEN H, SEBODE M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis[J]. J Hepatol, 2018, 68(4): 754-763. DOI: 10.1016/j.jhep.2017.11.020.
[36]	JANIK MK, KRUK B, SZCZEPANKIEWICZ B, et al. Measurement of liver and spleen stiffness as complementary methods for assessment of liver fibrosis in autoimmune hepatitis[J]. Liver Int, 2021, 41(2): 348-356. DOI: 10.1111/liv.14726.
[37]	LEFEBVRE T, WARTELLE-BLADOU C, WONG P, et al. Prospective comparison of transient, point shear wave, and magnetic resonance elastography for staging liver fibrosis[J]. Eur Radiol, 2019, 29(12): 6477-6488. DOI: 10.1007/s00330-019-06331-4.
[38]	MENDIZABAL M, MARCIANO S, VIDELA MG, et al. Fulminant presentation of autoimmune hepatitis: Clinical features and early predictors of corticosteroid treatment failure[J]. Eur J Gastroenterol Hepatol, 2015, 27(6): 644-648. DOI: 10.1097/MEG.0000000000000353.
[39]	ZIZZO AN, JIMENEZ-RIVERA C, KIM J, et al. A national retrospective study of paediatric end-stage liver disease as a predictor of change to second-line therapy in children with autoimmune hepatitis[J]. Liver Int, 2017, 37(10): 1562-1570. DOI: 10.1111/liv.13387.
[40]	BIEWENGA M, INDERSON A, TUSHUIZEN ME, et al. Early predictors of short-term prognosis in acute and acute severe autoimmune hepatitis[J]. Liver Transpl, 2020, 26(12): 1573-1581. DOI: 10.1002/lt.25906.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (596) PDF downloads(60)

Role of new noninvasive methods in guiding the diagnosis and treatment of autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2022.04.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Role of new noninvasive methods in guiding the diagnosis and treatment of autoimmune hepatitis

DOI: 10.3969/j.issn.1001-5256.2022.04.034

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content